de Jong, Daan L. K. published the artcileEffects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease: A Randomized Trial, Product Details of C17H18N2O6, the main research area is Alzheimers disease nilvadipine cerebral blood flow; Alzheimer disease; blood pressure; disease progression; hippocampus; nilvadipine.
Cerebrovascular changes, including reduced cerebral blood flow (CBF), occur early in the development of Alzheimer disease and may accelerate disease progression. This randomized, double-blind, placebo-controlled study investigated how 6 mo of treatment with the calcium antagonist nilvadipine would affect CBF in patients with mild-to-moderate Alzheimer disease. CBF was measured with magnetic resonance arterial spin labeling in whole-brain gray matter and in a priori defined regions of interest including the hippocampus. Fifty-eight patients were randomly assigned (29 in each group), of whom 22 in both groups had no magnetic resonance exclusion criteria and were medication compliant over 6 mo. Mean age was 72.8±6.2 years, mean mini-mental state examination was 20.4±3.4. Nilvadipine treatment lowered systolic blood pressure (Δ = -11.5 [95% CI, -19.7 to -3.2] mm Hg; P<0.01), while whole-brain gray-matter CBF remained stable (Δ = 5.4 [95% CI, -6.4 to 17.2] mL/100 g per min; P = 0.36). CBF in the hippocampus increased (left: Δ = 24.4 [95% CI, 4.3-44.5] mL/100 g per min; P = 0.02; right: Δ = 20.1 [95% CI, -0.6 to 40.8] mL/100 g per min; P = 0.06). There was no significant change in CBF in the posterior cingulate cortex (Δ = 5.2 [95% CI, -16.5 to 27.0] mL/100 g per min; P = 0.63) or other regions of interest. In conclusion, nilvadipine reduced blood pressure and increased CBF in the hippocampus, whereas other regions showed stable or small nonsignificant increases in CBF. These findings not only indicate preserved cerebral autoregulation in Alzheimer disease but also point toward beneficial cerebrovascular effects of antihypertensive treatment. Hypertension published new progress about Alzheimer disease. 21829-25-4 belongs to class pyridine-derivatives, name is Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C17H18N2O6, Product Details of C17H18N2O6.